Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · IEX Real-Time Price · USD
54.04
-0.26 (-0.48%)
At close: Jul 19, 2024, 4:00 PM
54.87
+0.83 (1.54%)
Pre-market: Jul 22, 2024, 7:11 AM EDT
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $862.99M in the twelve months ending March 31, 2024, with 22.41% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $195.88M with 20.81% year-over-year growth. In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth.
Revenue (ttm)
$862.99M
Revenue Growth
+22.41%
P/S Ratio
7.97
Revenue / Employee
$2,313,643
Employees
373
Market Cap
6.88B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
Dec 31, 2005 | 127.21K | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 87.77K | - | - |
Dec 31, 2001 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jazz Pharmaceuticals | 3.84B |
Exelixis | 1.85B |
Penumbra | 1.10B |
HealthEquity | 1.04B |
Ionis Pharmaceuticals | 776.62M |
Repligen | 607.45M |
Tempus AI | 562.02M |
Blueprint Medicines | 282.21M |
HALO News
- 5 days ago - Big Money Eyes Halozyme for Strong Growth - FXEmpire
- 27 days ago - Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis - PRNewsWire
- 4 weeks ago - Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy - PRNewsWire
- 6 weeks ago - Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook - PRNewsWire
- 6 weeks ago - Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform - PRNewsWire
- 6 weeks ago - Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - PRNewsWire
- 2 months ago - Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® - PRNewsWire
- 2 months ago - Halozyme to Participate in Upcoming Investor Conferences - PRNewsWire